Cargando…

Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study

The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real‐life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Valenti, Luca, Pelusi, Serena, Aghemo, Alessio, Gritti, Sara, Pasulo, Luisa, Bianco, Cristiana, Iegri, Claudia, Cologni, Giuliana, Degasperi, Elisabetta, D’Ambrosio, Roberta, del Poggio, Paolo, Soria, Alessandro, Puoti, Massimo, Carderi, Isabella, Pigozzi, Marie Graciella, Carriero, Canio, Spinetti, Angiola, Zuccaro, Valentina, Memoli, Massimo, Giorgini, Alessia, Viganò, Mauro, Rumi, Maria Grazia, Re, Tiziana, Spinelli, Ombretta, Colombo, Maria Chiara, Quirino, Tiziana, Menzaghi, Barbara, Lorini, Gianpaolo, Pan, Angelo, D’Arminio Monforte, Antonella, Buscarini, Elisabetta, Autolitano, Aldo, Bonfanti, Paolo, Terreni, Natalia, Aimo, Gianpiero, Mendeni, Monia, Prati, Daniele, Lampertico, Pietro, Colombo, Massimo, Fagiuoli, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948549/
https://www.ncbi.nlm.nih.gov/pubmed/34811949
http://dx.doi.org/10.1002/hep4.1851
_version_ 1784674679297933312
author Valenti, Luca
Pelusi, Serena
Aghemo, Alessio
Gritti, Sara
Pasulo, Luisa
Bianco, Cristiana
Iegri, Claudia
Cologni, Giuliana
Degasperi, Elisabetta
D’Ambrosio, Roberta
del Poggio, Paolo
Soria, Alessandro
Puoti, Massimo
Carderi, Isabella
Pigozzi, Marie Graciella
Carriero, Canio
Spinetti, Angiola
Zuccaro, Valentina
Memoli, Massimo
Giorgini, Alessia
Viganò, Mauro
Rumi, Maria Grazia
Re, Tiziana
Spinelli, Ombretta
Colombo, Maria Chiara
Quirino, Tiziana
Menzaghi, Barbara
Lorini, Gianpaolo
Pan, Angelo
D’Arminio Monforte, Antonella
Buscarini, Elisabetta
Autolitano, Aldo
Bonfanti, Paolo
Terreni, Natalia
Aimo, Gianpiero
Mendeni, Monia
Prati, Daniele
Lampertico, Pietro
Colombo, Massimo
Fagiuoli, Stefano
author_facet Valenti, Luca
Pelusi, Serena
Aghemo, Alessio
Gritti, Sara
Pasulo, Luisa
Bianco, Cristiana
Iegri, Claudia
Cologni, Giuliana
Degasperi, Elisabetta
D’Ambrosio, Roberta
del Poggio, Paolo
Soria, Alessandro
Puoti, Massimo
Carderi, Isabella
Pigozzi, Marie Graciella
Carriero, Canio
Spinetti, Angiola
Zuccaro, Valentina
Memoli, Massimo
Giorgini, Alessia
Viganò, Mauro
Rumi, Maria Grazia
Re, Tiziana
Spinelli, Ombretta
Colombo, Maria Chiara
Quirino, Tiziana
Menzaghi, Barbara
Lorini, Gianpaolo
Pan, Angelo
D’Arminio Monforte, Antonella
Buscarini, Elisabetta
Autolitano, Aldo
Bonfanti, Paolo
Terreni, Natalia
Aimo, Gianpiero
Mendeni, Monia
Prati, Daniele
Lampertico, Pietro
Colombo, Massimo
Fagiuoli, Stefano
author_sort Valenti, Luca
collection PubMed
description The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real‐life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients treated between 2014 and 2018, 65.3% with advanced fibrosis, of whom 97.7% achieved viral eradication (NAVIGATORE‐Lombardia registry). In a subset (n = 748), liver stiffness measurement (LSM) was available at baseline and follow‐up. Higher body mass index (BMI; odds ratio [OR] 1.06 per kg/m(2), 1.03‐1.09) and diabetes (OR 2.01 [1.65‐2.46]) were independently associated with advanced fibrosis at baseline, whereas statin use was protective (OR 0.46 [0.35‐0.60]; P < 0.0001 for all). The impact of BMI was greater in those without diabetes (P = 0.003). Diabetes was independently associated with less pronounced LSM improvement after viral eradication (P = 0.001) and in patients with advanced fibrosis was an independent predictor of the most frequent clinical events, namely de novo hepatocellular carcinoma (HCC; hazard ratio [HR] 2.09 [1.20‐3.63]; P = 0.009) and cardiovascular events (HR 2.73 [1.16‐6.43]; P = 0.021). Metformin showed a protective association against HCC (HR 0.32 [0.11‐0.96]; P = 0.043), which was confirmed after adjustment for propensity score (P = 0.038). Diabetes diagnosis further refined HCC prediction in patients with compensated advanced chronic liver disease at high baseline risk (P = 0.024). Conclusion: Metabolic comorbidities were associated with advanced liver fibrosis at baseline, whereas statins were protective. In patients with advanced fibrosis, diabetes increased the risk of de novo HCC and of cardiovascular events. Optimization of metabolic comorbidities treatment by a multi‐disciplinary management approach may improve cardiovascular and possibly liver‐related outcomes.
format Online
Article
Text
id pubmed-8948549
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89485492022-03-29 Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study Valenti, Luca Pelusi, Serena Aghemo, Alessio Gritti, Sara Pasulo, Luisa Bianco, Cristiana Iegri, Claudia Cologni, Giuliana Degasperi, Elisabetta D’Ambrosio, Roberta del Poggio, Paolo Soria, Alessandro Puoti, Massimo Carderi, Isabella Pigozzi, Marie Graciella Carriero, Canio Spinetti, Angiola Zuccaro, Valentina Memoli, Massimo Giorgini, Alessia Viganò, Mauro Rumi, Maria Grazia Re, Tiziana Spinelli, Ombretta Colombo, Maria Chiara Quirino, Tiziana Menzaghi, Barbara Lorini, Gianpaolo Pan, Angelo D’Arminio Monforte, Antonella Buscarini, Elisabetta Autolitano, Aldo Bonfanti, Paolo Terreni, Natalia Aimo, Gianpiero Mendeni, Monia Prati, Daniele Lampertico, Pietro Colombo, Massimo Fagiuoli, Stefano Hepatol Commun Original Articles The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real‐life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients treated between 2014 and 2018, 65.3% with advanced fibrosis, of whom 97.7% achieved viral eradication (NAVIGATORE‐Lombardia registry). In a subset (n = 748), liver stiffness measurement (LSM) was available at baseline and follow‐up. Higher body mass index (BMI; odds ratio [OR] 1.06 per kg/m(2), 1.03‐1.09) and diabetes (OR 2.01 [1.65‐2.46]) were independently associated with advanced fibrosis at baseline, whereas statin use was protective (OR 0.46 [0.35‐0.60]; P < 0.0001 for all). The impact of BMI was greater in those without diabetes (P = 0.003). Diabetes was independently associated with less pronounced LSM improvement after viral eradication (P = 0.001) and in patients with advanced fibrosis was an independent predictor of the most frequent clinical events, namely de novo hepatocellular carcinoma (HCC; hazard ratio [HR] 2.09 [1.20‐3.63]; P = 0.009) and cardiovascular events (HR 2.73 [1.16‐6.43]; P = 0.021). Metformin showed a protective association against HCC (HR 0.32 [0.11‐0.96]; P = 0.043), which was confirmed after adjustment for propensity score (P = 0.038). Diabetes diagnosis further refined HCC prediction in patients with compensated advanced chronic liver disease at high baseline risk (P = 0.024). Conclusion: Metabolic comorbidities were associated with advanced liver fibrosis at baseline, whereas statins were protective. In patients with advanced fibrosis, diabetes increased the risk of de novo HCC and of cardiovascular events. Optimization of metabolic comorbidities treatment by a multi‐disciplinary management approach may improve cardiovascular and possibly liver‐related outcomes. John Wiley and Sons Inc. 2021-11-22 /pmc/articles/PMC8948549/ /pubmed/34811949 http://dx.doi.org/10.1002/hep4.1851 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Valenti, Luca
Pelusi, Serena
Aghemo, Alessio
Gritti, Sara
Pasulo, Luisa
Bianco, Cristiana
Iegri, Claudia
Cologni, Giuliana
Degasperi, Elisabetta
D’Ambrosio, Roberta
del Poggio, Paolo
Soria, Alessandro
Puoti, Massimo
Carderi, Isabella
Pigozzi, Marie Graciella
Carriero, Canio
Spinetti, Angiola
Zuccaro, Valentina
Memoli, Massimo
Giorgini, Alessia
Viganò, Mauro
Rumi, Maria Grazia
Re, Tiziana
Spinelli, Ombretta
Colombo, Maria Chiara
Quirino, Tiziana
Menzaghi, Barbara
Lorini, Gianpaolo
Pan, Angelo
D’Arminio Monforte, Antonella
Buscarini, Elisabetta
Autolitano, Aldo
Bonfanti, Paolo
Terreni, Natalia
Aimo, Gianpiero
Mendeni, Monia
Prati, Daniele
Lampertico, Pietro
Colombo, Massimo
Fagiuoli, Stefano
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study
title Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study
title_full Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study
title_fullStr Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study
title_full_unstemmed Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study
title_short Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study
title_sort dysmetabolism, diabetes and clinical outcomes in patients cured of chronic hepatitis c: a real‐life cohort study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948549/
https://www.ncbi.nlm.nih.gov/pubmed/34811949
http://dx.doi.org/10.1002/hep4.1851
work_keys_str_mv AT valentiluca dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT pelusiserena dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT aghemoalessio dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT grittisara dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT pasuloluisa dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT biancocristiana dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT iegriclaudia dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT colognigiuliana dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT degasperielisabetta dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT dambrosioroberta dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT delpoggiopaolo dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT soriaalessandro dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT puotimassimo dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT carderiisabella dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT pigozzimariegraciella dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT carrierocanio dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT spinettiangiola dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT zuccarovalentina dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT memolimassimo dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT giorginialessia dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT viganomauro dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT rumimariagrazia dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT retiziana dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT spinelliombretta dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT colombomariachiara dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT quirinotiziana dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT menzaghibarbara dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT lorinigianpaolo dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT panangelo dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT darminiomonforteantonella dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT buscarinielisabetta dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT autolitanoaldo dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT bonfantipaolo dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT terreninatalia dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT aimogianpiero dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT mendenimonia dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT pratidaniele dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT lamperticopietro dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT colombomassimo dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT fagiuolistefano dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy
AT dysmetabolismdiabetesandclinicaloutcomesinpatientscuredofchronichepatitiscareallifecohortstudy